<SEC-DOCUMENT>0001193125-24-236708.txt : 20241011
<SEC-HEADER>0001193125-24-236708.hdr.sgml : 20241011
<ACCEPTANCE-DATETIME>20241011160141
ACCESSION NUMBER:		0001193125-24-236708
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20241011
DATE AS OF CHANGE:		20241011

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Iterum Therapeutics plc
		CENTRAL INDEX KEY:			0001659323
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L2
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-267795
		FILM NUMBER:		241367538

	BUSINESS ADDRESS:	
		STREET 1:		FITZWILLIAM COURT, 1ST FLOOR
		STREET 2:		LEESON CLOSE
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 YW24
		BUSINESS PHONE:		(872) 225-6077

	MAIL ADDRESS:	
		STREET 1:		FITZWILLIAM COURT, 1ST FLOOR
		STREET 2:		LEESON CLOSE
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 YW24

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Iterum Therapeutics Ltd
		DATE OF NAME CHANGE:	20151124
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d882769d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>(To Prospectus
dated October&nbsp;17, 2022)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-267795</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g882769g1011183518893.jpg" ALT="LOGO" STYLE="width:3.03403in;height:0.59375in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Up to $1,713,895 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Ordinary Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus
supplement amends and supplements certain information in the prospectus, dated October&nbsp;17, 2022, filed with the Securities and Exchange Commission as a part of our registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT>
(File <FONT STYLE="white-space:nowrap">No.&nbsp;333-267795),</FONT> or the Prior Prospectus, relating to the offer and sale of a number of our ordinary shares, nominal value $0.01 per share, that does not exceed the lesser of (1)&nbsp;a number of
ordinary shares having an aggregate offering price of up to $16,000,000, (2) the number of our authorized but unissued ordinary shares (after deducting the number of ordinary shares issuable upon exercise, conversion or exchange of our outstanding
securities or otherwise reserved for future issuance), and (3)&nbsp;the number or dollar amount of ordinary shares that would cause this offering to not satisfy the requirements for use of Form <FONT STYLE="white-space:nowrap">S-3,</FONT> including,
if applicable, General Instruction I.B.6 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> as described below, pursuant to the at the market offering agreement, or the Sales Agreement, we previously entered into with H.C. Wainwright&nbsp;&amp;
Co., LLC, or Wainwright. This prospectus supplement should be read in conjunction with the Prior Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in
the Prior Prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the Prior Prospectus and any future amendments or supplements thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus supplement, we have sold 4,052,640 ordinary shares for aggregate gross proceeds of $9,115,406.01 in
accordance with the Sales Agreement under the Prior Prospectus. We are filing this prospectus supplement to amend the Prior Prospectus to update the remaining aggregate offering amount of ordinary shares we are eligible to sell in accordance with
the Sales Agreement. We currently may offer and sell under the Sales Agreement a remaining number of our ordinary shares that does not exceed the lesser of (i)&nbsp;a number of ordinary shares having an aggregate offering price of up to $1,713,895,
after deducting the aggregate gross proceeds of ordinary shares previously sold in accordance with the Sales Agreement under the Prior Prospectus, (ii)&nbsp;the number of our authorized but unissued ordinary shares (after deducting the number of
ordinary shares issuable upon exercise, conversion or exchange of our outstanding securities or otherwise reserved for future issuance), and (iii)&nbsp;the number or dollar amount of ordinary shares that would cause this offering to not satisfy the
requirements for use of Form <FONT STYLE="white-space:nowrap">S-3,</FONT> including, if applicable, General Instruction I.B.6 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> as described below.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to General Instruction I.B.6 of Form <FONT STYLE="white-space:nowrap">S-3,</FONT> in no event may we sell, pursuant to the
registration statement of which this prospectus supplement and the Prior Prospectus are a part, securities in a public primary offering with a value exceeding <FONT STYLE="white-space:nowrap">one-third</FONT> of the aggregate market value of our
issued and outstanding ordinary shares held by <FONT STYLE="white-space:nowrap">non-affiliates,</FONT> or our public float, in any <FONT STYLE="white-space:nowrap">12-month</FONT> period, so long as our public float remains below $75,000,000. Our
public float as of October 10, 2024 is $29,758,789.68, based on 22,208,052 ordinary shares issued and outstanding and held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> on October&nbsp;10, 2024, and a price of $1.34 per share, the last
reported sale price of our ordinary shares on August&nbsp;20, 2024. As of the date hereof, we have sold securities with an aggregate market value of $8,205,700.78 pursuant to General Instruction I.B.6 of Form
<FONT STYLE="white-space:nowrap">S-3</FONT> during the prior <FONT STYLE="white-space:nowrap">12-month</FONT> period that ends on and includes the date hereof. As a result of the limitations of General Instruction I.B.6 of Form <FONT
STYLE="white-space:nowrap">S-3,</FONT> and in accordance with the terms of the Sales Agreement, we may currently offer and sell remaining ordinary shares having an aggregate offering price of up to $1,713,895 from time to time through Wainwright. If
our public float increases such that we may sell a greater amount of our ordinary shares under the Sales Agreement and the registration statement of which this prospectus supplement and the Prior Prospectus are a part, we will file another
prospectus supplement prior to making such sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2024, we had 43,681,345 authorized but unissued ordinary
shares (after deducting the number of ordinary shares issuable upon exercise, conversion or exchange of our outstanding securities or otherwise reserved for future issuance). Based on an assumed offering price per share of $0.93, which was the last
reported sale price of our ordinary shares on Nasdaq on October&nbsp;10, 2024, we have sufficient authorized ordinary shares available for issuance such that we can issue the maximum number of shares permitted under General Instruction I.B.6 of Form
<FONT STYLE="white-space:nowrap">S-3.</FONT> In no event will we sell, pursuant to the registration statement of which this prospectus forms a part, more ordinary shares than we have available and authorized for issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ordinary shares are listed on The Nasdaq Capital Market under the symbol &#147;ITRM.&#148; The last reported sale price of our ordinary
shares on October 10, 2024, was $0.93 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in our ordinary shares involves risks. See &#147;Risk Factors&#148; on page
<FONT STYLE="white-space:nowrap">SA-8</FONT> of the Prior Prospectus, and in the filings with the Securities and Exchange Commission that are incorporated by reference into the Prior Prospectus Supplement and this prospectus supplement, for certain
risks you should consider. You should read all the information set forth in this prospectus supplement and the Prior Prospectus, as well as the documents incorporated by reference herein and the Prior Prospectus, carefully before you make your
investment decision. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or
disapproved of these securities or determined if the Prior Prospectus, this prospectus supplement or the accompanying prospectus are truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>H.C. Wainwright&nbsp;&amp; Co. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is October 11, 2024 </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g882769g1011183518893.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g882769g1011183518893.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  X 1\# 2(  A$! Q$!_\0
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M_J.#_*N&I2]G4M+8VC+FC='RKX.LCK?CG2K>3YO.NQ(^>X!W'^5?8  50!T
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M<&IVJ02M)'Y;B2-HVP58=#114JE!1Y;:%.M-RYKZA#IP6Z2ZN)FN)XU*QLP
3" ]< =SBKU%%5&*CL3*3EN?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
